Spaceflight-associated Motion Sickness in Commercial Crew Astronauts
Abstract
Spaceflight-associated motion sickness, including space motion sickness (SMS) and terrestrial readaptation motion sickness (TRMS), has presented as the most operationally limiting effect on the human in the days following a gravity transition. Published data suggest that astronaut head movements provoke symptoms, but those studies rarely controlled for them. Most previous studies use postflight retrospective reporting and have not quantified temporal dynamics or persistence of symptoms; no study has published motion sickness in a cohort of commercial flyers. Here, we comprehensively evaluate SMS and TRMS within commercial flyers (N=8; 4F, 4M) for the first time, across two commercial missions of short duration (Polaris Dawn and Fram2). Utilizing a standard reporting methodology, we find an 87.5% incidence of SMS, which persisted for at least three days on orbit in 25% of crewmembers. The symptoms included vomiting in 62.5% of crewmembers. Regarding TRMS, incidence was 50%, severity was significantly lower than SMS (p = 0.007), and it tended to persist for a shorter duration than SMS for these short-duration flights. These findings establish a systematic baseline for spaceflight-associated motion sickness, informing its operational impact and salience as human spaceflight missions expand in accessibility and scope.
Related
- Stability of Antibody Repertoires in Astronauts During Long-Term Spaceflight
- Feeder- and Drinker-Associated Microbiota Differ from Host-Associated Fecal Microbiota During a Commercial Broiler Production Cycle with Age-Associated Changes in Taxonomic Composition.
- Longitudinal analysis of vaccine-associated alterations in the faecal microbiota of layer chickens using a vaccination schedule representative of commercial practice
- Replacing a farm-mixed diet with a commercial complete feed increases laying rate and is associated with physiological and cecal microbial changes in late-laying local crossbred hens
- A defined rumen-native microbial consortium is associated with reduced culling risk across commercial dairy herds
BibTeX
@misc{clark2026spaceflightassociated,
title = {{Spaceflight-associated Motion Sickness in Commercial Crew Astronauts}},
author = {Torin K. Clark and Aaron A. Allred and Jaime Mateus and Marissa Rosenberg},
howpublished = {arXiv},
year = {2026},
month = oct,
doi = {10.48550/arxiv.2610.24216},
eprint = {2610.24216},
archivePrefix = {arXiv},
url = {https://arxiv.org/abs/2610.24216},
note = {CC BY 4.0},
}
RIS
TY - UNPB
TI - Spaceflight-associated Motion Sickness in Commercial Crew Astronauts
AU - Torin K. Clark
AU - Aaron A. Allred
AU - Jaime Mateus
AU - Marissa Rosenberg
PY - 2026
DA - 2026/10/16
PB - arXiv
DO - 10.48550/arxiv.2610.24216
UR - https://arxiv.org/abs/2610.24216
AB - Spaceflight-associated motion sickness, including space motion sickness (SMS) and terrestrial readaptation motion sickness (TRMS), has presented as the most operationally limiting effect on the human in the days following a gravity transition. Published data suggest that astronaut head movements provoke symptoms, but those studies rarely controlled for them. Most previous studies use postflight retrospective reporting and have not quantified temporal dynamics or persistence of symptoms; no study has published motion sickness in a cohort of commercial flyers. Here, we comprehensively evaluate SMS and TRMS within commercial flyers (N=8; 4F, 4M) for the first time, across two commercial missions of short duration (Polaris Dawn and Fram2). Utilizing a standard reporting methodology, we find an 87.5% incidence of SMS, which persisted for at least three days on orbit in 25% of crewmembers. The symptoms included vomiting in 62.5% of crewmembers. Regarding TRMS, incidence was 50%, severity was significantly lower than SMS (p = 0.007), and it tended to persist for a shorter duration than SMS for these short-duration flights. These findings establish a systematic baseline for spaceflight-associated motion sickness, informing its operational impact and salience as human spaceflight missions expand in accessibility and scope.
ER -